GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

Everyone aspires to live a healthy life. The catch is that health is a moving target. It’s a challenge that changes as people ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

DR NELLY KAMWALEKenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 diabetes and obesity. Two drugs, Semaglutide and Tirzepatide ...

At the intersection of aesthetics and science, RegenCen is changing how patients think about aging. Born from a fusion of ...

This new class of GLP-1 weight loss drugs may feel like a miracle, but it still takes effort from you for these meds to work safely and effectively.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.